JP7680184B2 - ４，５－縮環１，２，４－トリアゾロン - Google Patents

４，５－縮環１，２，４－トリアゾロン Download PDF

Info

Publication number
JP7680184B2
JP7680184B2 JP2019522867A JP2019522867A JP7680184B2 JP 7680184 B2 JP7680184 B2 JP 7680184B2 JP 2019522867 A JP2019522867 A JP 2019522867A JP 2019522867 A JP2019522867 A JP 2019522867A JP 7680184 B2 JP7680184 B2 JP 7680184B2
Authority
JP
Japan
Prior art keywords
group
alkyl
fluoro
oxo
triazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535689A (ja
JP2019535689A5 (enExample
Inventor
シュテファン・ニコラウス・グラドル
デュイ・グエン
クヌート・アイス
ユーディト・ギュンター
ティモ・シュテルフェルト
アンドレアス・ヤンツァー
ズヴェン・クリスティアン
トマス・ミュラー
シェリフ・エル・シェイク
ハン・ジエ・ジョウ
チャンジア・ジャオ
デイヴィッド・ビー・サイクス
スティーヴン・ジェームズ・フェラーラ
ケリー・リュウ
サイモン・アンソニー・ハーバート
クラウディア・メルツ
ミヒャエル・ニーヘス
カール・フリードリッヒ・ニジング
マルティーナ・シェーファー
カチャ・ツィンマーマン
イェルク・クネーブライン
カイ・テーデ
トマス・ファウペル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JP2019535689A publication Critical patent/JP2019535689A/ja
Publication of JP2019535689A5 publication Critical patent/JP2019535689A5/ja
Priority to JP2022103480A priority Critical patent/JP2022130571A/ja
Priority to JP2024030029A priority patent/JP7747799B2/ja
Application granted granted Critical
Publication of JP7680184B2 publication Critical patent/JP7680184B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/02—Oxidoreductases acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12Y106/02004—NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019522867A 2016-10-27 2017-10-25 ４，５－縮環１，２，４－トリアゾロン Active JP7680184B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022103480A JP2022130571A (ja) 2016-10-27 2022-06-28 ４，５－縮環１，２，４－トリアゾロン
JP2024030029A JP7747799B2 (ja) 2016-10-27 2024-02-29 ４，５－縮環１，２，４－トリアゾロン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/103642 2016-10-27
CNPCT/CN2016/103642 2016-10-27
PCT/EP2017/077301 WO2018077944A2 (en) 2016-10-27 2017-10-25 4,5-annulated 1,2,4-triazolones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022103480A Division JP2022130571A (ja) 2016-10-27 2022-06-28 ４，５－縮環１，２，４－トリアゾロン

Publications (3)

Publication Number Publication Date
JP2019535689A JP2019535689A (ja) 2019-12-12
JP2019535689A5 JP2019535689A5 (enExample) 2020-12-03
JP7680184B2 true JP7680184B2 (ja) 2025-05-20

Family

ID=60293935

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019522867A Active JP7680184B2 (ja) 2016-10-27 2017-10-25 ４，５－縮環１，２，４－トリアゾロン
JP2022103480A Pending JP2022130571A (ja) 2016-10-27 2022-06-28 ４，５－縮環１，２，４－トリアゾロン
JP2024030029A Active JP7747799B2 (ja) 2016-10-27 2024-02-29 ４，５－縮環１，２，４－トリアゾロン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022103480A Pending JP2022130571A (ja) 2016-10-27 2022-06-28 ４，５－縮環１，２，４－トリアゾロン
JP2024030029A Active JP7747799B2 (ja) 2016-10-27 2024-02-29 ４，５－縮環１，２，４－トリアゾロン

Country Status (8)

Country Link
US (2) US10968216B2 (enExample)
EP (1) EP3532474B1 (enExample)
JP (3) JP7680184B2 (enExample)
CN (2) CN114921391B (enExample)
CA (1) CA3041650A1 (enExample)
TW (1) TW201827430A (enExample)
UY (1) UY37460A (enExample)
WO (1) WO2018077944A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114921391B (zh) 2016-10-27 2024-01-02 拜耳股份有限公司 4,5-环状1,2,4-三唑酮
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
TW201945346A (zh) 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
TW202043208A (zh) * 2019-01-11 2020-12-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
MX2022002470A (es) * 2019-08-29 2022-03-22 Janssen Biotech Inc Inhibidores de dihidroorotato deshidrogenasa sustituidos con urea.
AU2020363021A1 (en) * 2019-10-10 2022-04-07 Janssen Biotech, Inc. Bi-aryl dihydroorotate dehydrogenase inhibitors
JP7653456B2 (ja) * 2020-05-29 2025-03-28 メッドシャイン ディスカバリー インコーポレイテッド トリアゾロン系化合物
KR20230039678A (ko) * 2020-07-14 2023-03-21 난징 젠샤인 파마슈티컬스 컴퍼니, 리미티드 Dhodh 억제제로서의 화합물
CN111773214B (zh) * 2020-07-17 2021-04-20 中国人民解放军军事科学院军事医学研究院 2,4,5-三取代的1,2,4-三唑酮在制备抗病毒药物中的用途
WO2022070069A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
PE20240767A1 (es) * 2021-04-16 2024-04-17 Hotspot Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de trastornos
CN117616026A (zh) * 2021-07-05 2024-02-27 微境生物医药科技(上海)有限公司 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途
WO2023093812A1 (zh) * 2021-11-26 2023-06-01 南京明德新药研发有限公司 三氮唑酮类化合物的晶型及其应用
AU2023306375A1 (en) * 2022-07-12 2025-02-06 Hotspot Therapeutics, Inc. Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer
JP2025523056A (ja) * 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド 細胞増殖関連疾患の処置方法におけるｃｂｌ－ｂ阻害剤、ｃｂｌ－ｂ阻害剤を含む組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19627901A1 (de) 1996-07-11 1998-01-15 Bayer Ag Substituierte aromatische Carbonylverbindungen und ihre Derivate
DE19901846A1 (de) 1999-01-19 2000-07-20 Bayer Ag Substituierte Arylheterocyclen
US6444613B1 (en) 1999-03-12 2002-09-03 Hoechst Schering Agrevo Gmbh Defoliant
EP1352054A2 (en) * 2000-10-30 2003-10-15 Pharmacia Corporation Aspergillus ochraceus 11 alpha hydrolase and oxidoreductase
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
CA2746221A1 (en) 2008-12-08 2010-07-08 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
CN102574786A (zh) 2009-04-02 2012-07-11 默克雪兰诺有限公司 二氢乳清酸脱氢酶抑制剂
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP3456820B1 (de) * 2010-12-16 2024-06-19 Pharmazell GmbH Neuartige 7beta-hydroxysteroid dehydrogenase-mutanten und verfahren zur herstellung von ursodesoxycholsäure
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
EP2914729B1 (en) * 2012-11-01 2022-01-26 The University of British Columbia Cytochrome p450 and cytochrome p450 reductase polypeptides, encoding nucleic acid molecules and uses thereof
PT3019482T (pt) 2013-02-25 2018-11-28 Aurigene Discovery Tech Ltd Derivados de benzotriazole trissubstituídos enquanto inibidores de di-hidro-orotato-oxigenase
CN104561093A (zh) * 2014-12-25 2015-04-29 华东师范大学 一种重组人源CYP3A4/CPR/cyt b5蛋白共转染共表达的方法
US20160251341A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted triazole compounds as serine protease inhibitors
CN106543139B (zh) 2015-09-17 2020-03-17 沈阳中化农药化工研发有限公司 一种三唑酮类化合物及其用途
CN114921391B (zh) 2016-10-27 2024-01-02 拜耳股份有限公司 4,5-环状1,2,4-三唑酮
JOP20190094A1 (ar) * 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer
TW201945346A (zh) * 2018-04-10 2019-12-01 德商拜耳廠股份有限公司 2,4,5-三取代的1,2,4-三唑酮之製備方法
US20190307728A1 (en) * 2018-04-10 2019-10-10 Bayer Pharma Aktiengesellschaft Methods of treatment with a 2,4,5-trisubstituted 1,2,4-triazolone
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer

Also Published As

Publication number Publication date
JP2022130571A (ja) 2022-09-06
WO2018077944A3 (en) 2018-06-14
CA3041650A1 (en) 2018-05-03
UY37460A (es) 2018-05-31
US11787797B2 (en) 2023-10-17
CN110248937A (zh) 2019-09-17
TW201827430A (zh) 2018-08-01
US10968216B2 (en) 2021-04-06
CN110248937B (zh) 2022-03-29
JP7747799B2 (ja) 2025-10-01
EP3532474A2 (en) 2019-09-04
CN114921391B (zh) 2024-01-02
US20210188846A1 (en) 2021-06-24
WO2018077944A2 (en) 2018-05-03
CN114921391A (zh) 2022-08-19
EP3532474B1 (en) 2024-03-27
JP2019535689A (ja) 2019-12-12
JP2024063131A (ja) 2024-05-10
US20190375747A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP7747799B2 (ja) ４，５－縮環１，２，４－トリアゾロン
US12486248B2 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH
TWI791581B (zh) 二酮
CA3137472A1 (en) Acyl sulfonamides for treating cancer
CA3216503A1 (en) Phosphorus derivatives as novel sos1 inhibitors
EP3917915A1 (en) 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases
WO2017207534A1 (en) Substituted heteroarylbenzimidazole compounds
HK40086116A (zh) 用作dhodh抑制剂的2，4，5-三取代的1，2，4-三唑酮
WO2020157189A1 (en) 1,2,4-triazin-6(1h)-one compounds for the treatment of hyperproliferative diseases
WO2020048831A1 (en) 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
EA039707B1 (ru) 2,4,5-трехзамещенные 1,2,4-триазолоны, способы их получения, промежуточные соединения, фармацевтическая композиция и применение соединений для лечения гиперпролиферативного заболевания

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221215

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230112

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230116

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230203

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250508

R150 Certificate of patent or registration of utility model

Ref document number: 7680184

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150